Potential drug targets for asthma identified through mendelian randomization analysis

Abstract Background The emergence of new molecular targeted drugs marks a breakthrough in asthma treatment, particularly for severe cases. Yet, options for moderate-to-severe asthma treatment remain limited, highlighting the urgent need for novel therapeutic drug targets. In this study, we aimed to...

Full description

Saved in:
Bibliographic Details
Main Authors: Xingxuan Chen, Yu Shang, Danting Shen, Si Shi, Zhe Wen, Lijuan Li, Hong Chen
Format: Article
Language:English
Published: BMC 2025-01-01
Series:Respiratory Research
Subjects:
Online Access:https://doi.org/10.1186/s12931-024-03086-5
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832594497092976640
author Xingxuan Chen
Yu Shang
Danting Shen
Si Shi
Zhe Wen
Lijuan Li
Hong Chen
author_facet Xingxuan Chen
Yu Shang
Danting Shen
Si Shi
Zhe Wen
Lijuan Li
Hong Chen
author_sort Xingxuan Chen
collection DOAJ
description Abstract Background The emergence of new molecular targeted drugs marks a breakthrough in asthma treatment, particularly for severe cases. Yet, options for moderate-to-severe asthma treatment remain limited, highlighting the urgent need for novel therapeutic drug targets. In this study, we aimed to identify new treatment targets for asthma using the Mendelian randomization method and large-scale genome-wide association data (GWAS). Methods We utilized GWAS data from the UK Biobank (comprising 56,167 patients and 352,255 control subjects) and the FinnGen cohort (including 23,834 patients and 228,085 control subjects). Genetic instruments for 734 plasma proteins and 154 cerebrospinal fluid proteins were derived from recently published GWAS. Bidirectional Mendelian randomization analysis, Steiger filtering, colocalization, and phenotype scanning were employed for reverse causal inference detection, further substantiating the Mendelian randomization results. A protein-protein interaction network was also constructed to reveal potential associations between proteins and asthma medications. Results Under Bonferroni significance conditions, Mendelian randomization analysis revealed causal relationships between seven proteins and asthma. In plasma, we observed that an increase of one standard deviation in IL1R1[1.30 (95% CI 1.20–1.42)], IL7R[1.07 (95% CI 1.04–1.11)], ECM1[1.03 (95% CI 1.02–1.05)], and CD200R1[1.18 (95% CI 1.09–1.27)] were associated with an increased risk of asthma, while an increase in ADAM19 [0.87 (95% CI 0.82–0.92)] was found to be protective. In the brain, each 10-fold increase in IL-6 sRa [1.29 (95% CI 1.15–1.45)] was associated with an increased risk of asthma, while an increase in Layilin [0.61 (95% CI 0.51–0.73)] was found to be protective. None of the seven proteins exhibited a reverse causal relationship. Colocalization analysis indicated that ECM1 (coloc.abf-PPH4 = 0.953), IL-6 sRa (coloc.abf-PPH4 = 0.966), and layilin (coloc.abf-PPH4 = 0.975) shared the same genetic variation as in asthma. Conclusion A causal relationship exists between genetically determined protein levels of IL1R1, IL7R, ECM1, CD200R1, ADAM19, IL-6 sRa, and Layilin (LAYN) and asthma. Moreover, the identified proteins may serve as attractive drug targets for asthma, especially ECM1 and Layilin (LAYN). However, further research is required to comprehensively understand the roles of these proteins in the occurrence and progression of asthma.
format Article
id doaj-art-9a9f20e00ba84bf3a0efc5d810661d2e
institution Kabale University
issn 1465-993X
language English
publishDate 2025-01-01
publisher BMC
record_format Article
series Respiratory Research
spelling doaj-art-9a9f20e00ba84bf3a0efc5d810661d2e2025-01-19T12:36:24ZengBMCRespiratory Research1465-993X2025-01-0126111110.1186/s12931-024-03086-5Potential drug targets for asthma identified through mendelian randomization analysisXingxuan Chen0Yu Shang1Danting Shen2Si Shi3Zhe Wen4Lijuan Li5Hong Chen6Department of Pulmonary and Critical Care Medicine, The Second Affiliated Hospital of Harbin Medical UniversityDepartment of Respiratory Medicine, The Second Hospital of Heilongjiang ProvinceDepartment of Pulmonary and Critical Care Medicine, The Second Affiliated Hospital of Harbin Medical UniversityDepartment of Pulmonary and Critical Care Medicine, The Second Affiliated Hospital of Harbin Medical UniversityDepartment of Pulmonary and Critical Care Medicine, The Second Affiliated Hospital of Harbin Medical UniversityDepartment of Pulmonary and Critical Care Medicine, National Clinical Research Center of Respiratory Diseases, Friendship HospitalDepartment of Pulmonary and Critical Care Medicine, The Second Affiliated Hospital of Harbin Medical UniversityAbstract Background The emergence of new molecular targeted drugs marks a breakthrough in asthma treatment, particularly for severe cases. Yet, options for moderate-to-severe asthma treatment remain limited, highlighting the urgent need for novel therapeutic drug targets. In this study, we aimed to identify new treatment targets for asthma using the Mendelian randomization method and large-scale genome-wide association data (GWAS). Methods We utilized GWAS data from the UK Biobank (comprising 56,167 patients and 352,255 control subjects) and the FinnGen cohort (including 23,834 patients and 228,085 control subjects). Genetic instruments for 734 plasma proteins and 154 cerebrospinal fluid proteins were derived from recently published GWAS. Bidirectional Mendelian randomization analysis, Steiger filtering, colocalization, and phenotype scanning were employed for reverse causal inference detection, further substantiating the Mendelian randomization results. A protein-protein interaction network was also constructed to reveal potential associations between proteins and asthma medications. Results Under Bonferroni significance conditions, Mendelian randomization analysis revealed causal relationships between seven proteins and asthma. In plasma, we observed that an increase of one standard deviation in IL1R1[1.30 (95% CI 1.20–1.42)], IL7R[1.07 (95% CI 1.04–1.11)], ECM1[1.03 (95% CI 1.02–1.05)], and CD200R1[1.18 (95% CI 1.09–1.27)] were associated with an increased risk of asthma, while an increase in ADAM19 [0.87 (95% CI 0.82–0.92)] was found to be protective. In the brain, each 10-fold increase in IL-6 sRa [1.29 (95% CI 1.15–1.45)] was associated with an increased risk of asthma, while an increase in Layilin [0.61 (95% CI 0.51–0.73)] was found to be protective. None of the seven proteins exhibited a reverse causal relationship. Colocalization analysis indicated that ECM1 (coloc.abf-PPH4 = 0.953), IL-6 sRa (coloc.abf-PPH4 = 0.966), and layilin (coloc.abf-PPH4 = 0.975) shared the same genetic variation as in asthma. Conclusion A causal relationship exists between genetically determined protein levels of IL1R1, IL7R, ECM1, CD200R1, ADAM19, IL-6 sRa, and Layilin (LAYN) and asthma. Moreover, the identified proteins may serve as attractive drug targets for asthma, especially ECM1 and Layilin (LAYN). However, further research is required to comprehensively understand the roles of these proteins in the occurrence and progression of asthma.https://doi.org/10.1186/s12931-024-03086-5AsthmaDrug targetsMendelian randomizationTherapeutic targetsCerebrospinal fluid proteinsPlasma proteins
spellingShingle Xingxuan Chen
Yu Shang
Danting Shen
Si Shi
Zhe Wen
Lijuan Li
Hong Chen
Potential drug targets for asthma identified through mendelian randomization analysis
Respiratory Research
Asthma
Drug targets
Mendelian randomization
Therapeutic targets
Cerebrospinal fluid proteins
Plasma proteins
title Potential drug targets for asthma identified through mendelian randomization analysis
title_full Potential drug targets for asthma identified through mendelian randomization analysis
title_fullStr Potential drug targets for asthma identified through mendelian randomization analysis
title_full_unstemmed Potential drug targets for asthma identified through mendelian randomization analysis
title_short Potential drug targets for asthma identified through mendelian randomization analysis
title_sort potential drug targets for asthma identified through mendelian randomization analysis
topic Asthma
Drug targets
Mendelian randomization
Therapeutic targets
Cerebrospinal fluid proteins
Plasma proteins
url https://doi.org/10.1186/s12931-024-03086-5
work_keys_str_mv AT xingxuanchen potentialdrugtargetsforasthmaidentifiedthroughmendelianrandomizationanalysis
AT yushang potentialdrugtargetsforasthmaidentifiedthroughmendelianrandomizationanalysis
AT dantingshen potentialdrugtargetsforasthmaidentifiedthroughmendelianrandomizationanalysis
AT sishi potentialdrugtargetsforasthmaidentifiedthroughmendelianrandomizationanalysis
AT zhewen potentialdrugtargetsforasthmaidentifiedthroughmendelianrandomizationanalysis
AT lijuanli potentialdrugtargetsforasthmaidentifiedthroughmendelianrandomizationanalysis
AT hongchen potentialdrugtargetsforasthmaidentifiedthroughmendelianrandomizationanalysis